


Supplemental Figure Legends.

Supplemental Figure 1. Cohort selection. Breast cancer cohort selection workflow visualized.


Supplemental Figure 2. Prognostic value of FFAR4 in different breast cancer subtypes. Kaplan-Meier curves of patient outcomes based on FFAR4 expression. (A) RFS and (B) BCSS of Luminal A cohort (n = 75). (C) RFS and (D) BCSS of Luminal B HER2- cohort (n = 86). (E) RFS and (F) BCSS of Luminal B HER2+ cohort (n = 51). (G) RFS and (H) BCSS of HER2 non-luminal cohort (n = 41). (I) RFS and (J) BCSS of Triple negative cohort (n = 54). Bottom numbers indicate patient numbers at risk on different time points.

Supplemental Figure 1


Exploration cohort (n = 307)



Validation cohort 1 (n = 415)



Validation cohort 2 (n = 245)



Supplemental Figure 2

